A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
Clinical Pharmacology: Advances and Applications · 2014-11 · 179
DOI: 10.2147/cpaa.s61131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology: Advances and Applications, 2014-11. Verfasst von Charles Frost und 6 weiteren Autor:innen. Beteiligte Einrichtung: Exploratory Clinical and Translational Research, Bristol-Myers Squibb Company, Princeton, NJ, USA. Die Arbeit wurde bisher 34-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Exploratory Clinical and Translational Research, Bristol-Myers Squibb Company, Princeton, NJ, USA.
- Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb Company, Princeton, NJ, USA.
- Analytical and Bioanalytical Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
- Global Innovative Pharma Business Clinical Pharmacology, Pfizer Inc., Groton, CT, USA.
Zitieren
APA
Frost, C., Song, Y., Barrett, Y. C., Wang, J., Pursley, J., Boyd, R. A., & LaCreta, F. (2014). A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clinical Pharmacology: Advances and Applications, 179. https://doi.org/10.2147/cpaa.s61131
Vancouver
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clinical Pharmacology: Advances and Applications. 2014:179. doi:10.2147/cpaa.s61131
BibTeX
@article{Frost2014,
author = {Frost, Charles and Song, Yan and Barrett, Yu Chen and Wang, Jessie and Pursley, Janice and Boyd, Rebecca A and LaCreta, Frank},
title = {A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban},
journal = {Clinical Pharmacology: Advances and Applications},
year = {2014},
pages = {179},
doi = {10.2147/cpaa.s61131}
}
EUVIMED